Many Patients 80 Years and Older with Advanced Non-small Cell Lung Cancer (NSCLC) Can Tolerate Chemotherapy
作者： Ozden Altundag , David J. Stewart , Frank V. Fossella , Gregory D. Ayers , Wei Wei
DOI: 10.1097/JTO.0B013E3180311792
关键词:
摘要: People 80 years of age and older constitute 17.8% all lung cancer patients in the United States. Because life expectancies 80-year-old men women are 87.3 89.0 years, respectively, non-small cell shortens lives addition to causing morbidity. In this retrospective study, with chemotherapy-naive advanced treated at M. D. Anderson Cancer Center one or more follow-ups were identified from database for 1997 2004. A cohort younger than old was matched based on treatment year, race, histology, gender a 2:1 ratio. Of 13,690 thoracic oncology patients, 496 (3.6%) older, whom 46 met criteria. platinum doublets given 43% versus 79% (p < 0.0001), response rate 41% 47%, median progression-free survival 5.55 3.91 months = 0.216), overall 10.7 9.8 0.43). Hematologic nonhematologic toxicities similar. Our data indicate that selected may tolerate benefit chemotherapy, prospective evaluation these is indicated.
jto.org
utsystem.edu参考文章(23)
L. Repetto, A. Venturino, L. Fratino, D. Serraino, G. Troisi, W. Gianni, M. Pietropaolo, Geriatric oncology European Journal of Cancer. ,vol. 39, pp. 870- 880 ,(2003) , 10.1016/S0959-8049(03)00062-5
Annette L. Fitzpatrick, Lewis H. Kuller, Diane G. Ives, Oscar L. Lopez, William Jagust, John C. S. Breitner, Beverly Jones, Constantine Lyketsos, Corinne Dulberg, Incidence and Prevalence of Dementia in the Cardiovascular Health Study Journal of the American Geriatrics Society. ,vol. 52, pp. 195- 204 ,(2004) , 10.1111/J.1532-5415.2004.52058.X
P J Goodwin, F A Shepherd, Economic issues in lung cancer: a review. Journal of Clinical Oncology. ,vol. 16, pp. 3900- 3912 ,(1998) , 10.1200/JCO.1998.16.12.3900
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
Alastair J.J. Wood, Daniel C. Ihde, Chemotherapy of Lung Cancer The New England Journal of Medicine. ,vol. 327, pp. 1434- 1441 ,(1992) , 10.1056/NEJM199211123272006
M Di Maio, F Perrone, C Gallo, R V Iaffaioli, L Manzione, F V Piantedosi, S Cigolari, A Illiano, S Barbera, S F Robbiati, E Piazza, G P Ianniello, L Frontini, E Veltri, F Castiglione, F Rosetti, E De Maio, P Maione, C Gridelli, Supportive care in patients with advanced non-small-cell lung cancer. British Journal of Cancer. ,vol. 89, pp. 1013- 1021 ,(2003) , 10.1038/SJ.BJC.6601236
Yuh-Min Chen, Reury-Perng Perng, Mei-Chun Chen, Chun-Ming Tsai, Jacqueline Ming-Liu, Jacqueline Whang-Peng, A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer. ,vol. 40, pp. 221- 226 ,(2003) , 10.1016/S0169-5002(03)00031-X
Katsuyuki Hotta, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Mitsune Tanimoto, An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer. Lung Cancer. ,vol. 46, pp. 61- 76 ,(2004) , 10.1016/J.LUNGCAN.2004.02.018
A.B. Sandler, R. Gray, J. Brahmer, A. Dowlati, J.H. Schiller, M.C. Perry, D.H. Johnson, O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599 Lung Cancer. ,vol. 49, ,(2005) , 10.1016/S0169-5002(05)80220-X
M. Borges, J.P. Sculier, M. Paesmans, M. Richez, G. Bureau, G. Dabouis, J. Lecomte, J. Michel, O. Van Cutsem, J. Schmerber, V. Giner, M.C. Berchier, R. Sergysels, P. Mommen, J. Klastersky, Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC) Lung Cancer. ,vol. 16, pp. 21- 33 ,(1996) , 10.1016/S0169-5002(96)00609-5